Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

doi:10.1002/ajh.24377

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

American journal of hematology - 1 Jul 2016

Rotunno Giada, Pacilli Annalisa, Artusi Valentina, Rumi Elisa, Maffioli Margherita, Delaini Federica, Brogi Giada, Fanelli Tiziana, Pancrazzi Alessandro, Pietra Daniela, Bernardis Isabella, Belotti Clara, Pieri Lisa, Sant'Antonio Emanuela, Salmoiraghi Silvia, Cilloni Daniela, Rambaldi Alessandro, Passamonti Francesco, Barbui Tiziano, Manfredini Rossella, Cazzola Mario, Tagliafico Enrico, Vannucchi Alessandro M, Guglielmelli Paola

Abstract excerpt

Transformation to secondary myelofibrosis (MF) occurs as part of the natural history of polycythemia vera (PPV-MF) and essential thrombocythemia (PET-MF). Although primary (PMF) and secondary MF are considered similar diseases and managed similarly, there are few studies specifically focused on the latter. The aim of this study was to characterize the mutation landscape, and describe the main clinical correlates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Prognosis

Share to Survival Rate

Share to Thrombocythemia, Essential

Source

Open in PubMed

Identifiers

PMID: 27037840
DOI: 10.1002/ajh.24377

Genes

SRSF2
ASXL1
CALR
IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.PMID 27037840Read ↗

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation SequencingSemantic proximity Read ↗

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential ThrombocytosisSemantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

Genetic Risk Assessment in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Next-Generation Sequencing Mutational Landscape and Clinical Features of Chinese Adults with Myeloproliferative NeoplasmsSemantic proximity Read ↗

A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.Semantic proximity Read ↗

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.Semantic proximity Read ↗

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.Semantic proximity Read ↗

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.